Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes

详细信息    查看全文

• 作者：Michael K Wong (1)
  Howard L Kaufman (2)
  Gregory A Daniels (3)
  David F McDermott (4)
  Sandra Aung (5)
  James N Lowder (5)
  Michael A Morse (6)
  
  1. Department of Medicine ; University of Southern California ; Suite 3455 ; 1441 Eastlake Avenue ; Los Angeles ; CA ; 90033 ; USA
  2. Department of Surgery ; Rutgers Cancer Center Institute of New Jersey ; Room 2007 ; 195 Little Albany Street ; New Brunswick ; NJ ; 08901 ; USA
  3. Moores Cancer Center ; University of California San Diego ; 3855 Health Sciences Drive ; La Jolla ; CA ; 92093 ; USA
  4. Beth Israel Hospital Deaconess Medical Center ; Masco Building ; 375 Longwood Avenue ; Boston ; MA ; 02215 ; USA
  5. Prometheus Laboratories Inc. ; 9410 Carroll Park Drive ; San Diego ; CA ; 92121 ; USA
  6. Duke University Medical Center ; Mudd Building ; Rm 437 ; 10 Bryan Searle Drive ; Durham ; NC ; 27710 ; USA
  
• 关键词：Interleukin ; 2 ; Immunotherapy ; Cancer ; Cure ; Metastatic ; Melanoma ; Registry ; Renal cell carcinoma
• 刊名：Journal for Immunotherapy of Cancer
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：2
• 期：1
• 全文大小：235 KB
• 参考文献：1. National Cancer Database (NCDB) [cancer/ncdb/index.html" class="a-plus-plus">http://www.facs.org/cancer/ncdb/index.html]
  2. Surveillance, Epidemiology, and End Results (SEER) [cancer.gov/about/factsheets/SEER_brochure.pdf" class="a-plus-plus">http://seer.cancer.gov/about/factsheets/SEER_brochure.pdf]
  3. Horowitz, MM (2012) Does matched unrelated donor transplantation have the same outcome as matched sibling transplantation in unselected patients?. Best Pract Res Clin Haematol 25: pp. 483-486 CrossRef
  4. Center for International Bone Marrow Transplant Registry (CIBMTR) [http://www.cibmtr.org]
  5. Heng, DY, Xie, W, Regan, MM, Warren, MA, Golshayan, AR, Sahi, C, Eigl, BJ, Ruether, JD, Cheng, T, North, S, Venner, P, Knox, JJ, Chi, KN, Kollmannsberger, C, McDermott, DF, Oh, WK, Atkins, MB, Bukowski, RM, Rini, BI, Choueiri, TK (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27: pp. 5794-5799 CrossRef
  6. Alimohamed, N, Lee, JL, Srinivas, S, Bjarnason, GA, Knox, JJ, Mackenzie, MJ, Wood, L, Vaishampayan, UN, Tan, MH, Rha, SY, Donskov, F, Tantravahi, S, Kollmannsberger, C, North, S, Rini, BI, Choueiri, TK, Heng, DY (2013) A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma [abstract]. Clin Genitourin Cancer.
  7. Harshman, LC, Xie, W, Bjarnason, GA, Knox, JJ, MacKenzie, M, Wood, L, Srinivas, S, Vaishampayan, UN, Tan, MH, Rha, SY, Donskov, F, Agarwal, N, Kollmannsberger, C, North, S, Rini, BI, Heng, DY, Choueiri, TK (2012) Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol 13: pp. 927-935 CrossRef
  8. Hutson, TE, Escudier, B, Esteban, E, Bjarnason, GA, Lim, HY, Pittman, KB, Senico, P, Neithammer, A, Lu, DR, Hariharan, S, Motzer, RJ (2014) Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 32: pp. 760-767 3.50.3961" target="_blank" title="It opens in new window">CrossRef
  9. Motzer, RJ, Escudier, B, Oudard, S, Hutson, TE, Porta, C, Bracarda, S, Grunwald, V, Thompson, JA, Figlin, RA, Hollaender, N, Urbanowitz, G, Berg, WJ, Kay, A, Lebwohl, D, Ravaud, A (2008) RECORD-1 Study group: efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: pp. 449-456 36(08)61039-9" target="_blank" title="It opens in new window">CrossRef
  10. Rini, BI, Escudier, B, Tomczak, P, Kaprin, A, Szczylik, C, Hutson, TE, Michaelson, MD, Gorbunova, VA, Gore, ME, Rusakov, IG, Negrier, S, Ou, YC, Castellano, D, Lim, HY, Uemura, H, Tarazi, J, Cella, D, Chen, C, Rosbrook, B, Kim, S, Motzer, RJ (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378: pp. 1931-1939 36(11)61613-9" target="_blank" title="It opens in new window">CrossRef
  11. Motzer, RJ, Barrios, CH, Kim, TM, Falcon, S, Cosgriff, T, Harker, WG, Pittman, KB, Sabbatini, R, Rha, SY, Flaig, TW, Page, RD, Bavbek, SE, Beck, JT, Patel, PM, Schiff, E, Vaury, A, Niolat, J, Gogov, S, Anak, O, Knox, J (2013) Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol 31: pp. 4504 CrossRef
  12. O鈥橲ullivan, CG, Madan, RA, Gulley, JL (2014) Nivolumab: promising survival signal coupled with limited toxicity raises expectations. J Clin Oncol 32: pp. 1-2 3.53.2770" target="_blank" title="It opens in new window">CrossRef
  13. Schwartzentruber, DJ (2001) Guidelines for the safe administration of high-dose interleukin-2. J Immunother 24: pp. 287-293 371-200107000-00004" target="_blank" title="It opens in new window">CrossRef
  14. Kaufman, HL, Wong, KK, Daniels, GA, McDermott, DF, Aung, S, Lowder, JN, Morse, MA (2014) The use of registries to improve cancer treatment: a National Database for Patients Treated with Interleukin-2 (IL-2). J Personalized Med 4: pp. 52-64 3390/jpm4010052" target="_blank" title="It opens in new window">CrossRef
  15. Lowder, JN, Aung, S, Wong, KK, Daniels, GA, Kaufman, HL, McDermott, DF, Morse, MA (2014) High-dose interleukin-2 registry: PROCLAIM: Modern data on toxicities and outcomes [abstract]. J Clin Oncol 4: pp. 430
  16. Wong, KK, Daniels, GA, Kaufman, HL, McDermott, DF, Morse, MA, Aung, S, Lowder, JN (2013) High dose interleukin-2 registry, PROCLAIM, higher center-specific IL-2 dose density correlated with higher response rates [abstract]. J Immunol Ther Cancer 1: pp. P67 CrossRef
  17. HD IL-2 database [http://www.proclaimregistry.com]
  
• 刊物主题：Oncology;
• 出版者：BioMed Central
• ISSN：2051-1426

文摘

Cancer registries have proven valuable with respect to validating therapeutic safety and drug efficacy, uncovering real-world implementation practices, and their evolution over time. Modern cancer therapeutics are approved as single agents oftentimes compared to the least active approved standard agent in randomized trials. However, the burgeoning diversity and number of drugs introduces a complexity that quickly outstrips the knowledge provided by these pivotal trials. This gap in information is particularly relevant when survival is the primary therapeutic endpoint. In addition, the inherent complexity of the immune response will make registries a particularly important tool in expeditiously understanding solid tumor immunotherapy and patient outcomes.